MA56186A - Composés pour le traitement d'une maladie respiratoire - Google Patents
Composés pour le traitement d'une maladie respiratoireInfo
- Publication number
- MA56186A MA56186A MA056186A MA56186A MA56186A MA 56186 A MA56186 A MA 56186A MA 056186 A MA056186 A MA 056186A MA 56186 A MA56186 A MA 56186A MA 56186 A MA56186 A MA 56186A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- treatment
- respiratory disease
- respiratory
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1908451.6A GB201908451D0 (en) | 2019-06-12 | 2019-06-12 | Compounds for treating respiratory disease |
| GBGB1917691.6A GB201917691D0 (en) | 2019-12-04 | 2019-12-04 | Compounds for treating respiratory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56186A true MA56186A (fr) | 2022-04-20 |
Family
ID=71120193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056186A MA56186A (fr) | 2019-06-12 | 2020-06-12 | Composés pour le traitement d'une maladie respiratoire |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US12552770B2 (fr) |
| EP (1) | EP3983389A1 (fr) |
| JP (1) | JP7797206B2 (fr) |
| KR (1) | KR20220050126A (fr) |
| CN (1) | CN114269721B (fr) |
| AU (1) | AU2020290049A1 (fr) |
| BR (1) | BR112021025079A2 (fr) |
| CA (1) | CA3141394A1 (fr) |
| CL (1) | CL2021003275A1 (fr) |
| CO (1) | CO2022000084A2 (fr) |
| CR (1) | CR20220006A (fr) |
| IL (1) | IL288793A (fr) |
| MA (1) | MA56186A (fr) |
| MX (1) | MX2021015214A (fr) |
| PE (1) | PE20221003A1 (fr) |
| PH (1) | PH12021553110A1 (fr) |
| WO (1) | WO2020249957A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3196620A1 (fr) | 2020-10-05 | 2022-04-14 | Enliven Therapeutics, Inc. | Composes de 5- et 6-azaindole pour l'inhibition de tyrosine kinases bcr-abl |
| TW202237090A (zh) * | 2020-12-11 | 2022-10-01 | 英商Ｔｍｅｍ16Ａ有限公司 | 治療呼吸道疾病之化合物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2521907A1 (fr) * | 2003-04-10 | 2004-10-21 | Pfizer Inc. | Composes bicycliques comme antagonistes du recepteur nr2b |
| US20050239767A1 (en) * | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| US20060045953A1 (en) * | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
| JP2009001495A (ja) * | 2005-10-13 | 2009-01-08 | Taisho Pharmaceutical Co Ltd | ２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体 |
| US7772231B2 (en) * | 2005-12-29 | 2010-08-10 | Abbott Laboratories | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| AU2008285289A1 (en) * | 2007-08-03 | 2009-02-12 | Biomarin Iga Limited | Drug combinations for the treatment of Duchenne muscular dystrophy |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| KR20110138245A (ko) | 2009-03-16 | 2011-12-26 | 노키아 지멘스 네트웍스 오와이 | 요청되지 않은 통신을 방지하기 위한 통신 연결 설정 제어 |
| WO2011099832A2 (fr) * | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant |
| WO2013033269A1 (fr) * | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Monomères bioorthogonaux capables de se dimériser et de cibler des bromodomaines et procédés d'utilisation correspondant |
| MX2018002006A (es) | 2015-08-20 | 2018-06-19 | Boehringer Ingelheim Int | Benzamidas apareadas novedosas. |
| EP3868750A1 (fr) * | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulateurs de ror-gamma |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| CN108689942B (zh) * | 2017-04-11 | 2023-06-09 | 广东东阳光药业有限公司 | 含氮双环化合物及其制备方法和用途 |
| EP3612180B1 (fr) * | 2017-04-17 | 2023-10-11 | The Regents of the University of California | Arylamides d'acide 2-acylamino-cycloalkylthiophène-3-carboxylique substitués en tant qu'inhibiteurs du canal chlorure activé par le calcium tmem16a |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
| JP2021536458A (ja) * | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
-
2020
- 2020-06-12 KR KR1020227001065A patent/KR20220050126A/ko not_active Ceased
- 2020-06-12 CR CR20220006A patent/CR20220006A/es unknown
- 2020-06-12 WO PCT/GB2020/051415 patent/WO2020249957A1/fr not_active Ceased
- 2020-06-12 CA CA3141394A patent/CA3141394A1/fr active Pending
- 2020-06-12 EP EP20734266.8A patent/EP3983389A1/fr active Pending
- 2020-06-12 MA MA056186A patent/MA56186A/fr unknown
- 2020-06-12 PH PH1/2021/553110A patent/PH12021553110A1/en unknown
- 2020-06-12 CN CN202080049335.6A patent/CN114269721B/zh active Active
- 2020-06-12 JP JP2021573733A patent/JP7797206B2/ja active Active
- 2020-06-12 PE PE2021002069A patent/PE20221003A1/es unknown
- 2020-06-12 AU AU2020290049A patent/AU2020290049A1/en not_active Abandoned
- 2020-06-12 BR BR112021025079A patent/BR112021025079A2/pt not_active Application Discontinuation
- 2020-06-12 MX MX2021015214A patent/MX2021015214A/es unknown
-
2021
- 2021-12-08 IL IL288793A patent/IL288793A/en unknown
- 2021-12-09 CL CL2021003275A patent/CL2021003275A1/es unknown
- 2021-12-10 US US17/547,940 patent/US12552770B2/en active Active
-
2022
- 2022-01-07 CO CONC2022/0000084A patent/CO2022000084A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20220006A (es) | 2022-06-06 |
| WO2020249957A1 (fr) | 2020-12-17 |
| JP7797206B2 (ja) | 2026-01-13 |
| BR112021025079A2 (pt) | 2022-02-15 |
| CA3141394A1 (fr) | 2020-12-17 |
| CN114269721B (zh) | 2024-12-20 |
| IL288793A (en) | 2022-02-01 |
| CO2022000084A2 (es) | 2022-04-08 |
| US20220098167A1 (en) | 2022-03-31 |
| EP3983389A1 (fr) | 2022-04-20 |
| US12552770B2 (en) | 2026-02-17 |
| JP2022535980A (ja) | 2022-08-10 |
| PH12021553110A1 (en) | 2022-08-01 |
| CN114269721A (zh) | 2022-04-01 |
| MX2021015214A (es) | 2022-04-06 |
| CL2021003275A1 (es) | 2022-08-19 |
| PE20221003A1 (es) | 2022-06-15 |
| AU2020290049A1 (en) | 2022-02-03 |
| KR20220050126A (ko) | 2022-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3675859A4 (fr) | Composés, compositions et méthodes pour le traitement d'une maladie | |
| EP4301359A4 (fr) | Composés de liaison covalents pour le traitement d'une maladie | |
| EP3852735A4 (fr) | Agonistes du récepteur farnésoïde x pour le traitement d'une maladie | |
| MA52747A (fr) | Composés tétrahydro-1h-pyrazino[2,1-ajisoindolylquinoline pour le traitement d'une maladie auto-immune | |
| EP3820537A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| MA54229A (fr) | Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3935050A4 (fr) | Composés hétérocycliques pour traitement médical | |
| EP3737361A4 (fr) | Inhibiteurs de la dihydrocéramide désaturase pour le traitement d'une maladie | |
| EP3986863A4 (fr) | Inhibiteurs de glycolate oxydase pour le traitement d'une maladie | |
| MA55199A (fr) | Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie | |
| EP3924371A4 (fr) | Vecteurs de thérapie génique pour le traitement de la maladie de danon | |
| EP4034530A4 (fr) | Inhibiteurs de la protéine kinase i interagissant avec des récepteurs pour le traitement d'une maladie | |
| EP3432892A4 (fr) | Antagonistes dérivés du mannose de fimh utiles pour le traitement d'une maladie | |
| EP3504204A4 (fr) | Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie | |
| EP3846821A4 (fr) | Polythérapie destinée au traitement d'une maladie hépatique | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| EP3911329A4 (fr) | Composition pour la prévention ou le traitement d'une maladie du foie métabolique | |
| EP3749322A4 (fr) | Composés et méthodes de traitement d'une dépendance et de troubles associés | |
| EP4298094A4 (fr) | Analogues pour le traitement d'une maladie | |
| MA51738A (fr) | Composés pour le traitement de la douleur | |
| EP3648769A4 (fr) | N-acyl amides dérivés du microbiote humain pour le traitement d'une maladie humaine | |
| MA55141A (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP4052694A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire | |
| EP3730144A4 (fr) | Agent pour le traitement d'une maladie du système nerveux |